Clindamycin
Treatment for Cellulitis
Typical Dosage: 300-450mg orally every 6-8 hours
Effectiveness
85%
Safety Score
65%
Clinical Trials
8
Participants
35K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
300-450mg orally every 6-8 hours
Time to Effect
1-2 days
Treatment Duration
7 days
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25
Monitoring:$125
Side Effect Mgmt:$50
Total Annual:$200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$235.29
Cost per Remission
$250
Clindamycin Outcomes
for Cellulitis
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+80%
Common Side Effects
Diarrhea
+15%
Nausea
+7%
Abdominal pain
+7%
Rash
+1%
Sources:
Active Clinical Trials
3 active trials recruiting for Clindamycin in Cellulitis
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
NCT05899140RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Masokori, Sierra Leone
Started: Mar 15, 2024
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
NCT06982105RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Indianapolis, United States
Started: May 20, 2025
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404RECRUITING
5K participants
OBSERVATIONAL
Phoenix, United States +50 more
Started: Mar 5, 2020
Completed Clinical Trials
4 completed trials for Clindamycin in Cellulitis
Adjunctive Clindamycin for Cellulitis: C4C Trial.
NCT01876628COMPLETEDPHASE4
410 participants
INTERVENTIONAL
Bristol, United Kingdom
Started: Oct 1, 2013
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
NCT00352612COMPLETEDPHASE4
200 participants
INTERVENTIONAL
Baltimore, United States
Started: Sep 1, 2006
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
NCT00730028COMPLETEDPHASE2
1.31K participants
INTERVENTIONAL
San Francisco, United States +5 more
Started: Apr 1, 2009
Effective Antibiotic Treatment of MRSA
NCT00388310COMPLETEDNA
33 participants
INTERVENTIONAL
Newark, United States
Started: Feb 1, 2006